AngioLab (XKRX:251280) Change In Receivables : ₩-93.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Change In Receivables?

AngioLab's change in receivables for the quarter that ended in Dec. 2023 was ₩-93.8 Mil. It means AngioLab's Accounts Receivable increased by ₩93.8 Mil from Dec. 2022 to Dec. 2023 .

AngioLab's change in receivables for the fiscal year that ended in Dec. 2023 was ₩-93.8 Mil. It means AngioLab's Accounts Receivable increased by ₩93.8 Mil from Dec. 2022 to Dec. 2023 .

AngioLab's Accounts Receivable for the quarter that ended in Dec. 2023 was ₩83.7 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AngioLab's Days Sales Outstanding for the six months ended in Dec. 2023 was 30.74.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AngioLab's liquidation value for the six months ended in Dec. 2023 was ₩1,030.9 Mil.

AngioLab Change In Receivables Historical Data

The historical data trend for AngioLab's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Change In Receivables Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

706.11

66.14

-110.43

243.55

-93.77

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Change In Receivables	Get a 7-Day Free Trial			706.11	66.14	-110.43	243.55	-93.77

AngioLab Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-93.8 Mil.

AngioLab (XKRX:251280) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AngioLab's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	83.65	/	496.646	*	91
=	30.74

2. In Ben Graham's calculation of liquidation value, AngioLab's accounts receivable are only considered to be worth 75% of book value:

AngioLab's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2804.214	-	1949.978	+	0.75 * 83.65	+	0.5 * 227.864
=	1,030.9

AngioLab Change In Receivables Related Terms

Thank you for viewing the detailed overview of AngioLab's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines